Aktiesnakken — Maj 2011
-
BAC nu
-
NAMED PATIENTS!
-
thanks!
-
hvad betyder det? stop for indrullering
-
guidance virker utroværdig høj på expenses
-
arzerra, bulky tumors
-
de rekrutterer ikke flere i de forsøg der kører named patient
-
ingen pushback, det stopper bare omkostninger mest i de følgende år
-
de 80 mill zalu
-
gælder også 2012
-
total omkostninger sænkes, men ikke så meget gennemslag for 2011
-
zalu 31. juni er deadlinen
-
mere UBS
-
unibody hvorfor nævner i det ikke længere
-
subcut i EULAR
-
fase 3 i IV?
-
hard numbers appreciated
-
unibody er ikke god platform til cancer
-
og de har travlt med at diskutere både på duobody og unibody
-
men unibody fader
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind